CV Sciences (CVSI) Cash from Investing Activities Growth (1y) (2014 - 2026)
CV Sciences (CVSI) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 85.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.71% |
| Mar 31, 2026 | 92.50% |
| Dec 31, 2025 | 59.09% |
| Sep 30, 2025 | -132.35% |
| Jun 30, 2025 | -22.50% |
| Dec 31, 2024 | 85.90% |
| Mar 31, 2021 | 92.71% |
| Dec 31, 2020 | -6.91% |
| Sep 30, 2020 | 27.46% |
| Jun 30, 2020 | 94.22% |
| Mar 31, 2020 | -788.89% |
| Dec 31, 2019 | 69.96% |
| Sep 30, 2019 | -168.24% |
| Jun 30, 2019 | -561.76% |
| Mar 31, 2019 | 74.16% |
| Dec 31, 2018 | 58.92% |
| Jun 30, 2018 | -960.84% |
| Dec 31, 2017 | -329.18% |
| Dec 31, 2016 | 110.05% |
| Sep 30, 2016 | 99.22% |